Micro-Dose, Macro-Impact: Leveraging Psychedelics in Frontline Healthcare Workers During the COVID-19 Pandemic

• Status: Active, not recruiting
• Trial end date: 2021-04-01
• Target enrollment: 0
• Participant gender: All

Summary

A retrospective chart review of an open-label trial of low-dose ketamine administered to front-line Healthcare workers who were identified as experiencing acute stress disorder due to the COVID-19 Pandemic.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Limbic Medical
• Collaborator: Enovex Pharmacy
• Treatments: Ketamine

Criteria

Inclusion Criteria:

1. Greater than 18 years of age

2. Demonstrate capacity to consent to the study

3. A Frontline Health Care Worker-defined as any EMS personnel (firefighter, EMT, flight nurse, etc.), or any hospital-based worker (particularly in the ED, ICU, or OR) such as an RN, MD/DO, or non-clinical support staff (EVS, etc.)

4. Experiencing acute stress disorder as determined by clinically validated screening tools -

Exclusion Criteria:

1. Currently on prescription medications for psychiatric issues

2. Currently pregnant or breastfeeding or actively trying to get pregnant

3. History of seizure disorder, liver disease, or psychosis/mania

4. Uncontrolled Hypertension

5. Physician discretion: any condition deemed inappropriate that will increase the risk -